

To the Editor

Rome, April 30th, 2023

Dear Editor,

We strongly appreciate your consideration and your interest on our work and we spent all our efforts to ameliorate our manuscript manuscript ID 84458 entitled "MEPOLIZUMAB INDUCED PALMOPLANTAR PSORIASIS" by Artosi F and Diluvio L et al., according with the reviewers' suggestions in view of your kind re-consideration for publication in *World Journal of Clinical Cases Manuscript*

Below you will find a list of the responses/corrections we made.

Looking forward to your kind answer,

Best regards,

Fabio Artosi and Laura Diluvio and co-authors

- 1) We made the abstract more concise
- 2) We have made the introduction shorter and aimed at elucidating only the concepts useful for the analysis of the phenomenon described
- 3) We have integrated in the case presentation all the elements in our possession such as hematochemical alterations of the blood tests, the clinical photos of the palmar lesions before and after the treatment, the dermoscopic photos of the palmar lesions, the clinimetric scores of the disease, some information on the family history of atopy and some clinical and dermoscopic findings.
- 4) We have completely restructured the "Discussion" section. We have incorporated new evidence regarding the role of IL-5 as an immunomodulator in reducing Th1 axis activity in vitro. We included some evidence regarding the role of the cytokine IL-4 in modulating the cell-mediated/humoral response balance, and evidence of how dupilumab may alter this. In a specular way, it is hypothesized that it also occurred in the case presented.